A large real-world study shows improved glycemic outcomes for adults and children who initiate use of the Loop DIY automated insulin delivery system using community resources.
Children with familial type 1 diabetes have different characteristics to those with sporadic diabetes at presentation, but longer-term outcomes are similar, say researchers.
People with type 1 diabetes who are “hyperglycemia aversive” reduce their hyperglycemia exposure at the cost of increased hypoglycemia and, potentially, reduced hypoglycemia awareness, research suggests.
COVID-19 restrictions do not significantly impact glycated hemoglobin levels in individuals with type 2 diabetes, but those with poor psychologic wellbeing may experience worsening glycemic control, suggest findings from an Italian study.
Adding dapagliflozin to standard care improves outcomes for people with heart failure and reduced ejection fraction irrespective of sex, suggests a prespecified subgroup analysis of the DAPA-HF trial.
Findings from a US randomized controlled trial suggest that add-on treatment with the SGLT2 inhibitor dapagliflozin reduces levels of some vasoconstrictors and increases some vasodilators in people with type 2 diabetes.
Black West African men have lower levels of insulin secretion in response to a meal than their White Northern European counterparts, irrespective of insulin sensitivity, study findings indicate.
A Mendelian analysis supports a causal effect of hyperglycemia on stroke risk, and the researchers also pinpoint the medications most likely to reduce this risk.
Flash glucose monitoring is associated with small but sustained improvements in glycemic control and a reduction in severe hypoglycemia relative to self-monitoring of blood glucose in type 1 diabetes, observational data show.
Fear of hypoglycemia, rather than the actual frequency of hypoglycemic events, may impact diabetes-specific quality of life in adolescents, say researchers.
Older people with type 2 diabetes who initiate treatment with long-acting insulin analogs have a lower risk for severe hypoglycemia than those using neutral protamine Hagedorn insulin, real-world study findings suggest.
Research shows that COVID-19 mortality risk in people with type 2 diabetes varies only a little according to which antiglycemic medications they are taking at the time.
Empagliflozin has similar cardioprotective effects in people with heart failure regardless of whether or not they have recent volume overload, report the EMPEROR-Reduced investigators.
Patients with new-onset lupus nephritis may be more likely to achieve a complete renal response if initially given a higher dose of prednisone than currently recommended, findings indicate.
Readmission to hospital within a month of admission for diabetic ketoacidosis is common and associated with an increased mortality risk, say researchers.
A novel weekly insulin achieves similar glycemic control to insulin degludec at a higher fasting glucose target, report the investigators at the virtual ENDO 2021 meeting.